Suppr超能文献

脑膜败血伊丽莎白菌:关于一种新兴病原体及其相关治疗挑战的病例报告。

Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges.

作者信息

Tropea Fabrizio, Fraulino David, Aeschlimann Jeffrey, LaSala P Rocco, Magano Sonia

机构信息

University of Connecticut Health Center, Farmington, CT, United States.

University of Connecticut School of Pharmacy, Storrs, CT, United States.

出版信息

IDCases. 2025 May 7;40:e02248. doi: 10.1016/j.idcr.2025.e02248. eCollection 2025.

Abstract

is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed hosts with an immunocompromised status and/or a prolonged exposure to healthcare settings. Herein, we report a case of a 78-year-old male with newly diagnosed myelodysplastic syndrome initially admitted to the hospital with pneumonia and then re-admitted after discharge with septic shock and evidence of bacteremia isolated from blood cultures. Treatment with piperacillin-tazobactam was initiated and later escalated to dual-therapy with the addition of levofloxacin. After hemodynamic stability was achieved, the patient was discharged on oral levofloxacin to complete a 21-day course of therapy. displays a unique multi-drug resistant profile that often makes initial antimicrobial selection challenging. This case illustrates the importance of early detection and use of in vitro susceptibility testing to guide therapeutic decision-making in infections; a pathogen known to have both high morbidity and mortality particularly in the immunocompromised.

摘要

是一种革兰氏阴性杆菌,以前被认为很少感染人类,但最近已被确认为社区和医院环境中的一种新兴病原体。这种微生物通常存在于环境中,已被证明会感染免疫功能低下和/或长期暴露于医疗环境中的易感宿主。在此,我们报告一例78岁男性,新诊断为骨髓增生异常综合征,最初因肺炎入院,出院后因感染性休克再次入院,血培养分离出菌血症证据。开始使用哌拉西林-他唑巴坦治疗,后来升级为联合左氧氟沙星的双联治疗。血流动力学稳定后,患者口服左氧氟沙星出院,完成21天疗程的治疗。表现出独特的多重耐药谱,这常常使初始抗菌药物选择具有挑战性。该病例说明了早期检测和使用体外药敏试验以指导感染治疗决策的重要性;这种病原体已知具有高发病率和死亡率,尤其是在免疫功能低下的患者中。

相似文献

1
Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges.
IDCases. 2025 May 7;40:e02248. doi: 10.1016/j.idcr.2025.e02248. eCollection 2025.
3
Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: The first case series from India.
South Asian J Cancer. 2013 Oct;2(4):211-5. doi: 10.4103/2278-330X.119912.
4
Multidrug resistant Elizabethkingia meningoseptica bacteremia - Experience from a level 1 trauma centre in India.
Intractable Rare Dis Res. 2018 Aug;7(3):172-176. doi: 10.5582/irdr.2018.01077.
5
A Rare Case of Elizabethkingia meningoseptica Bacteremia After Liver Transplantation.
Am J Case Rep. 2021 Nov 20;22:e933992. doi: 10.12659/AJCR.933992.
6
Clinical features and outcomes of critically ill patients with Elizabethkingia meningoseptica: an emerging pathogen.
Acute Crit Care. 2021 Aug;36(3):256-261. doi: 10.4266/acc.2020.01158. Epub 2021 Jul 26.
7
Risk factors and outcome of levofloxacin-resistant Elizabethkingia meningoseptica bacteraemia in adult patients in Taiwan.
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1373-1380. doi: 10.1007/s10096-017-2942-7. Epub 2017 Mar 7.
8
Bacteremia due to Elizabethkingia meningoseptica.
IDCases. 2015 Jan 17;2(1):13-5. doi: 10.1016/j.idcr.2015.01.002. eCollection 2015.
9
An Emerging Nosocomial Pathogen Causing Septicemia in Critically Ill Patients.
Indian J Crit Care Med. 2019 Feb;23(2):104-105. doi: 10.5005/jp-journals-10071-23127.
10
Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia.
Int J Antimicrob Agents. 2018 Jan;51(1):47-51. doi: 10.1016/j.ijantimicag.2017.05.018. Epub 2017 Jun 28.

本文引用的文献

1
bloodstream infections in severely immunocompromised patients: persistent, relapsing and associated with high mortality.
JAC Antimicrob Resist. 2024 Oct 25;6(5):dlae161. doi: 10.1093/jacamr/dlae161. eCollection 2024 Oct.
2
In Vitro and In Vivo Antimicrobial Activities of Vancomycin and Rifampin against .
Int J Mol Sci. 2023 Nov 30;24(23):17012. doi: 10.3390/ijms242317012.
3
Elizabethkingia anophelis Is the Dominant Elizabethkingia Species Found in Blood Cultures in Singapore.
J Clin Microbiol. 2018 Feb 22;56(3). doi: 10.1128/JCM.01445-17. Print 2018 Mar.
4
Insights from the draft genome into the pathogenicity of a clinical isolate of Em3.
Stand Genomic Sci. 2017 Sep 16;12:56. doi: 10.1186/s40793-017-0269-8. eCollection 2017.
5
Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica.
Int J Antimicrob Agents. 2017 Oct;50(4):507-511. doi: 10.1016/j.ijantimicag.2017.06.021. Epub 2017 Jul 10.
6
Elizabethkingia meningoseptica: Emerging nosocomial pathogen in bedside hemodialysis patients.
Indian J Crit Care Med. 2013 Sep;17(5):304-7. doi: 10.4103/0972-5229.120323.
8
Elizabethkingia meningoseptica: an emerging pathogen causing meningitis in a hospitalized adult trauma patient.
Indian J Med Microbiol. 2013 Jul-Sep;31(3):293-5. doi: 10.4103/0255-0857.115653.
10
Tigecycline and colistin susceptibility of Chryseobacterium meningosepticum isolated from blood in Taiwan.
Int J Antimicrob Agents. 2009 Jul;34(1):100-1. doi: 10.1016/j.ijantimicag.2009.01.011. Epub 2009 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验